| Bioactivity | (R)-Zunsemetinib is the inactive isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases[1]. |
| Name | (R)-Zunsemetinib |
| CAS | 1640282-44-5 |
| Formula | C25H22ClF2N5O3 |
| Molar Mass | 513.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor [2]. Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine [3]. Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325. |
(R)-Zunsemetinib
CAS: 1640282-44-5 F: C25H22ClF2N5O3 W: 513.92
(R)-Zunsemetinib is the inactive isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunseme
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.